Background/Objectives: Mitochondrial diseases (MDs) are heterogeneous genetic disorders caused by oxidative phosphorylation impairment, governed by both mitochondrial DNA (mtDNA) and nuclear DNA (nDNA). Traditional multi-step diagnostic strategies, involving mtDNA long-range PCR and screening of a limited set of nuclear genes, often leave many patients without a molecular diagnosis. This study evaluates the clinical implementation of a single-step MITO-NUCLEAR Next-Generation (NGS) panel (whole mtDNA and 254 nuclear genes), previously developed and validated by our group. Methods: Buccal swab DNA from 70 patients with suspected MDs was sequenced using an optimized probe dilution ratio (1:500, mtDNA: nDNA), achieving mean depths of ~10,000× (mtDNA) and 110× (nDNA). Variants were classified according to ACMG/AMP guidelines and their mtDNA-specific specifications. Results: Ninety unique variants were identified (86.7% nuclear). A definitive molecular diagnosis was reached in 17% of patients, compared with 5.7% for mtDNA analysis alone: four primary mtDNA defects (MT-TS1, MT-CYB, MT-TL1, MT-ATP6), two nuclear-encoded mitochondrial disorders (ECHS1, FH) and six non-mitochondrial phenocopies (WFS1, ATP7B, G6PC1, ABCA4, KIF1A). A possible diagnosis was reached in 20% of patients, 46% were carriers of monoallelic variants in recessive genes, and 17% were negative. Conclusions: Simultaneous MITO-NUCLEAR NGS testing significantly increases diagnostic yield over single-genome screening. This single-step targeted panel offers a fast and efficient tool that facilitates variant identification across both genomes, supporting accurate clinical management and timely familial genetic counseling.